Michel Dahan - Jan 31, 2024 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, Chief Operating Officer
Signature
/s/ Carolyn Rucci, attorney-in-fact for Michel Dahan
Stock symbol
AKBA
Transactions as of
Jan 31, 2024
Transactions value $
$0
Form type
4
Date filed
2/2/2024, 04:11 PM
Previous filing
May 25, 2023
Next filing
Feb 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Award $0 +149K +25.87% $0.00 726K Jan 31, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Stock Option (Right to buy) Award $0 +224K $0.00 224K Jan 31, 2024 Common Stock 224K $1.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F2 Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
F3 The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.